Phase 1 Head and Neck Cancer Trial, Recruiting NCT06540443 Sponsor: MegaPro Biomedical Co. Ltd. Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Phase 1 Head and Neck Cancer Trial, Recruiting

NCT06540443
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 20 years or older
  • People who have been diagnosed through a tissue biopsy with a specific type of head and neck cancer (squamous cell carcinoma), or who have suspicious lymph nodes that may indicate cancer spread, at a certain stage of disease, and who have not yet had surgery for this condition
  • People whose treating doctor has determined that lymph node removal surgery is needed within 8 weeks, based on standard care at the trial site
  • People who are not currently breastfeeding
  • People who are able to understand and are willing to sign a written consent form
  • People who are able to follow the study's procedures and requirements

Who may not be able to join:

  • People who have a medical reason why they cannot have an MRI scan
  • People with a history of serious allergic reactions, or a known allergy to ingredients found in the contrast agents used in this study (including gadolinium-based agents, SPIO particles, or iodine-based contrast agents)
  • People who had a gadolinium-enhanced MRI scan within 7 days before enrolling in the trial
  • People who took part in another imaging-related clinical trial within 30 days before enrolling
  • People with active widespread infections, significant active heart conditions, active stomach or intestinal ulcers, or other health conditions that may seriously affect how the study contrast agent works in the body
  • People with kidney disease or reduced kidney function
  • People with liver or spleen disease or problems, identified through other scans (such as CT or MRI) or lab results
  • People with an active hepatitis B or hepatitis C infection
  • People with bone marrow disorders or a history of bone marrow transplant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Pei-Jen Lou, MD., PhD, National Taiwan University Hospital

Phone: +886-35910360

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
MegaPro Biomedical Co. Ltd.
Registry
ClinicalTrials.gov
Start date
19 December 2024
Est. completion
1 June 2026

Where this trial is recruiting

🇹🇼 Taiwan

Primary endpoints

Sensitivity and Specificity of MPB-2043 Enhanced MRI in Detecting Lymph Node Metastasis

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov